Overall, our findings suggest autotaxin/LPA signalling mediates obesity‐related cardiac injuries, and administration of specific autotaxin inhibitor is a potential therapeutic approach to improve cardiomyopathy. Here, ENPP2 is linked to obesity due to melanocortin 4 receptor deficiency.